MiMedx Group Inc

Most Recent

  • uploads///Part  Graph
    Company & Industry Overviews

    How Did Ziopharm Keep XBI from Losing More Ground?

    Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.

    By Peter Neil
  • uploads///GMED SGA
    Company & Industry Overviews

    A Deep Look at Globus Medical’s Financial Performance

    In 3Q17, Globus Medical (GMED) generated sales of $151.7 million compared to $135.6 million in 3Q16.

    By Kenneth Smith
  • uploads///GMED analysts reco
    Company & Industry Overviews

    Analyst Ratings for Globus Medical and Its Peers in February

    Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold.”

    By Kenneth Smith
  • uploads///MDXG EPS Trend
    Company & Industry Overviews

    Behind MiMedx Group’s Recent Financial Performance

    In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.

    By Kenneth Smith
  • uploads///pain injection market
    Company & Industry Overviews

    Why the Physician Office Pain Management Market Matters to MiMedx

    Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.

    By Kenneth Smith
  • uploads///MDXG RD Trend
    Company & Industry Overviews

    Which Markets Is MiMedx Group Actually Targeting?

    MiMedx estimates that the domestic skin and dermal substitute market will reach sales of $1.1 billion in 2020.

    By Kenneth Smith
  • uploads///MDXG _revenue growth
    Company & Industry Overviews

    Understanding MiMedx Group’s Zealous Focus on Sales

    MiMedx focuses on marketing efforts to increase revenues. The company has at its disposal a sales force of 320 professionals.

    By Kenneth Smith
  • uploads///MDXGanalysts Reco
    Company & Industry Overviews

    MiMedx Group on the Street: Analyst Recommendations in January

    Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.